Efficacy and Safety of Anlotinib in Adjuvant Therapy for High-grade Soft Tissue Sarcoma

Summary

To evaluate the efficacy and safety of Anlotinib Hydrochloride Capsule combined with Best Supportive Therapy in the adjuvant treatment of patients with high-grade soft tissue sarcoma after operation, as compared with placebo combined with Best Supportive Therapy.

Timeline

Start

2019-05-13

Primary completion

2022-06-01

Completion

2022-12-31

Publications

• Wang C, Hu X, Yang L, Xu Y, Zheng B, Yang J, Liao Z, Sun Z, Zhang S, Yu L, Yan Y, Chen Y, Fujiwara T, Zhang J, Buhtoiarov IN, Sun Y, Yan W. Anlotinib versus Placebo as Adjuvant Therapy for Localized High-Grade Soft-Tissue Sarcomas: A Phase II, Double-Blinded, Randomized Controlled Trial. Clin Cancer Res. 2025 Apr 1;31(7):1194-1203. doi: 10.1158/1078-0432.CCR-24-2531.

Drugs

Indications